Last reviewed · How we verify
NCT05955027: QTc-ZX-7101A
A Study to Evaluate the Effect of a Single Oral Dose of ZX-7101A on the QTc Interval in Healthy Subjects
Phase 1 trial testing ZX-7101A in Influenza, Human in 24 participants. Completed in 15 December 2023.
5 August 2023
Quick facts
| Lead sponsor | Nanjing Zenshine Pharmaceuticals |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 24 |
| Start date | 8 July 2023 |
| Primary completion | 5 August 2023 |
| Estimated completion | 15 December 2023 |
| Sites | 1 location across China |
Drugs / interventions tested
- ZX-7101A — full drug profile →
- Placebo
Conditions studied
- Influenza, Human — all drugs for Influenza, Human →
Sponsor
Nanjing Zenshine Pharmaceuticals — full company profile →
Who can join
Adults 18 to 45, any sex, with Influenza, Human. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to evaluate the effect of a single oral dose of ZX-7101A on the QTc interval in healthy subjects.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05955027
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of ZX-7101A
Trials testing the same drug.
- NCT06669351 — Study to Assess the Safety and Efficacy of ZX-7101A in Children Aged 5-11 Years With Influenza · Phase 3 · terminated
- NCT06099873 — Study to Assess the Safety and Efficacy of ZX-7101A in Adolescents With Influenza · Phase 3 · completed
- NCT06057103 — A Study to Evaluate Drug-drug Interaction of ZX-7101A Tablets and Oseltamivir Phosphate Capsules in Healthy Adult Subjec · Phase 1 · completed
- NCT05949385 — A Study to Assess the Effect of Itraconazole Capsules on the Pharmacokinetics of ZX-7101A Tablets in Healthy Adult Subje · Phase 1 · completed
- NCT05702489 — A Study to Evaluate the Efficacy and Safety of ZX-7101A Tablets in Adults with Uncomplicated Influenza · Phase 2, PHASE3 · completed
Other recruiting trials for Influenza, Human
Currently open trials in the same condition.
- NCT07204964 — A Study to Evaluate the Immune Response and Safety of an Influenza Vaccine in Adults 18 Years of Age and Above · Phase 2 · active not recruiting
- NCT07121192 — A Study to Assess the Immune Response and Safety of a Vaccine Against Influenza in Adults 18 Years of Age and Older · Phase 2 · active not recruiting
- NCT05921448 — Vaccine Pandemic Preparedness Through Airway Immunology Characterization · EARLY_PHASE1 · active not recruiting
- NCT06573008 — Study of GP681 Tablets Compared With Placebo in Patients With Influenza at High Risk of Influenza Complications · Phase 3 · recruiting
- NCT06622590 — Phase I Clinical Trial of Quadrivalent Influenza Virus Split Vaccine · Phase 1 · active not recruiting
Other Nanjing Zenshine Pharmaceuticals trials
Trials by the same sponsor.
- NCT07310134 — Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of ZX-8177 in Patients With Adva · Phase 1 · recruiting
- NCT07095257 — Study to Assess the Safety and Efficacy of ZX-7101A for Oral Suspension in Chinese Pediatric Participants 2 to 11 Years · Phase 3 · completed
- NCT06841926 — Study to Evaluate the Pharmacokinetics and Relative Bioavailability of Metabolites in Healthy Chinese Adult Males · Phase 1 · completed
- NCT06669351 — Study to Assess the Safety and Efficacy of ZX-7101A in Children Aged 5-11 Years With Influenza · Phase 3 · terminated
- NCT06099873 — Study to Assess the Safety and Efficacy of ZX-7101A in Adolescents With Influenza · Phase 3 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05955027 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Nanjing Zenshine Pharmaceuticals
- Last refreshed: 4 November 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05955027.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing